| Drug | Dosage | Dose form | Cost* |
|---|---|---|---|
| Gepotidacin (Blujepa) | 1,500 mg twice daily for 5 days | 750-mg tablet | $1,900 for 20 750-mg tablets |
*—Estimated retail price of one course of treatment. Actual cost will vary with insurance and by region. Information obtained at https://www.goodrx.com (accessed September 2, 2026; zip code: 66211).
Gepotidacin (Blujepa) is a bactericidal antibiotic labeled for the treatment of uncomplicated urinary tract infections (UTIs) in female patients 12 years and older weighing at least 40 kg (88 lb). Its mechanism of action to inhibit DNA replication is slightly different from the fluoroquinolone drug class. Gepotidacin is also labeled for the treatment of uncomplicated urogenital gonorrhea in male and female patients 12 years and older.
SAFETY
The main safety concern with gepotidacin is QTc prolongation with a theoretical risk of arrhythmia induction. It should not be used in patients with a history of QTc prolongation, with relevant cardiac disease, or who are taking other medications that prolong the QTc interval. Strong cytochrome P450 3A4 inhibitors (eg, itraconazole, clarithromycin, grapefruit juice), severe renal impairment (estimated glomerular filtration rate less than 30 mL/min/1.73 m2), and severe hepatic impairment (Child-Pugh class C) raise gepotidacin serum levels and may increase QTc prolongation risk.1
Gepotidacin reversibly inhibits acetylcholinesterase.1 Patients taking neuromuscular blocking agents or anticholinergic medications should be monitored while being treated with gepotidacin. Dysarthria, syncope, and muscle spasms have been reported in clinical trials.1Clostridioides difficile infection may occur (in less than 1% of patients) and requires evaluation if diarrhea develops. No data are available on the use of gepotidacin in pregnant patients to evaluate for risks of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. No data are available on the presence of gepotidacin in breastmilk or its effects on breastfeeding infants.
TOLERABILITY
The most common adverse effects are diarrhea (14% to 18%), nausea (8% to 11%), and abdominal pain (4%). In premarketing studies, 3% to 6% of patients discontinued treatment with gepotidacin due to adverse effects, compared with 2% of patients taking nitrofurantoin.1
EFFECTIVENESS
Gepotidacin was studied in two randomized trials that enrolled 3,136 female patients 12 years and older who weighed at least 40 kg with uncomplicated UTIs due to Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus, or Enterococcus faecalis.2,3 A 5-day course of gepotidacin was similar to nitrofurantoin for complete symptom resolution and microbiological eradication between days 10 and 13 (50.6% vs 47% in trial 1 and 58.5% vs 46% in trial 2). In the second trial, a similar proportion of participants required treatment with a second antibiotic due to lack of symptom resolution. Studies to determine if treatment with gepotidacin is a viable option for pregnant patients and female patients younger than 12 years would be useful given the limited treatment options available for these populations.
Gepotidacin has not been compared with other commonly used antibiotics such as trimethoprim, trimethoprim/sulfamethoxazole, or fosfomycin. Effectiveness for treating multidrug-resistant uropathogens or pyelonephritis is unknown. In a recent study, gepotidacin was shown to be comparable with ceftriaxone plus azithromycin in treating uncomplicated urogenital gonorrhea.4 In this study, neither regimen met the World Health Organization criterion of 95% effectiveness for treatment of gonorrhea (92.6% vs 91.2% microbiological success). Current available safety data for treatment of gonorrhea may be different than UTI treatment because the participants in this study were mostly men and medications were given at higher doses.
Read the full article
Get immediate access, anytime, anywhere.
Choose a single article, issue, or full-access subscription.
Earn up to 14 CME credits per issue.
